1. Home
  2. CXII vs MNPR Comparison

CXII vs MNPR Comparison

Compare CXII & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CXII

Churchill Capital Corp XII Class A Ordinary Shares

N/A

Current Price

$10.49

Market Cap

597.4M

Sector

Finance

ML Signal

N/A

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

SELL

Current Price

$72.00

Market Cap

587.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CXII
MNPR
Founded
2026
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
597.4M
587.4M
IPO Year
2026
2019

Fundamental Metrics

Financial Performance
Metric
CXII
MNPR
Price
$10.49
$72.00
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $130.17
AVG Volume (30 Days)
27.3K
★ 121.1K
Earning Date
N/A
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.99
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.05
$50.07
52 Week High
$10.99
$124.82

Technical Indicators

Market Signals
Indicator
CXII
MNPR
Relative Strength Index (RSI) 44.45 44.76
Support Level $10.34 $66.88
Resistance Level $10.45 $75.20
Average True Range (ATR) 0.03 4.84
MACD 0.02 1.02
Stochastic Oscillator 41.18 63.28

Price Performance

Historical Comparison
CXII
MNPR

About CXII Churchill Capital Corp XII Class A Ordinary Shares

Churchill Capital Corp XII is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: